Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer.

Abstract

Aim: To assess symptoms, healthcare resource utilizationand health-related quality of lifein advanced renal cell carcinoma (aRCC) clinical practice. Materials & methods: TheUSA point-in-time survey of physiciansand patients wasconducted between February and September 2019. Results: Data were available for 227 patients. Mean (standard deviation) number of symptoms was 3.4 (3.2); differences were observed across International Metastatic RCC Database Consortiumrisk categories (p<0.001), with fewer symptoms in favorable-risk patients. Disease burden, measured by greater healthcare resource utilizationand worse health-related quality of life, was high, particularly in International Metastatic RCC Database Consortium intermediate- or poor-versus favorable-risk patients. In total, 45 patients (21.6%) were hospitalized due to aRCC within a 6-month period, 35 (16.8%) had one hospitalizationand ten (4.8%) experienced ≥2 hospitalizations due to aRCC. Mean (standard deviation) 19-Item Functional Assessment of Cancer Therapy Kidney Symptom Index score was 53.6 (13.2) for this population, significantly lower than the reference value (59.8; p<0.001). Conclusion: A clear need exists for improved disease management in patients with aRCC.